Cambridge, MA, United States
Cambridge, MA, United States

Time filter

Source Type

Patent
Blueprint Medicines | Date: 2016-10-17

Compounds and compositions useful for treating disorders related to Kit are described herein.


Patent
Blueprint Medicines | Date: 2016-08-26

This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.


Patent
Blueprint Medicines | Date: 2016-04-13

Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.


Patent
Blueprint Medicines | Date: 2016-04-07

Compounds and compositions useful for treating disorders related to KIT and PDFGR are described herein.


Patent
Blueprint Medicines | Date: 2015-04-17

The invention provides MET gene fusions. MET fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with MET fusions, such as conditions mediated by aberrant MET expression or activity or overexpression of MET.


Patent
Blueprint Medicines | Date: 2015-10-20

Compounds and compositions useful for treating disorders related to mutant KIT are described herein.


Patent
Blueprint Medicines | Date: 2015-04-02

Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.


Patent
Blueprint Medicines | Date: 2015-08-04

Compounds and compositions useful for treating disorders related to Kit are described herein.


Patent
Blueprint Medicines | Date: 2016-07-22

Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.


Patent
Blueprint Medicines | Date: 2015-01-14

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.

Loading Blueprint Medicines collaborators
Loading Blueprint Medicines collaborators